Please ensure Javascript is enabled for purposes of website accessibility

Gilead Fixes the Price of COVID-19 Drug Remdesivir; the Government Secures the Bulk of Its Supply

By Eric Volkman – Jun 29, 2020 at 6:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In the U.S., a health insurer insurer should be billed $3,120 per treatment course.

Remdesivir, a malaria drug that has been repurposed to treat COVID-19 and currently represents the best hope for attacking the disease, now has a price tag. On Monday, the company behind the medication, Gilead Sciences (GILD 0.40%), said it will be sold at $390 per vial. Therefore, the basic price for a five-day treatment course using six vials would be $2,340.

Gilead added that "[b]ecause of the way the U.S. system is set up and the discounts that government healthcare programs expect," the price for U.S. private insurance companies will be $520 per vial. This equates to $3,120 per treatment course, with the patient's final bill depending on the policy's coverage.

Gloved hands holding a vial of medicine.

Image source: Gilead Sciences.

Subsequent to the pharmaceutical company's news, the federal Department of Health and Human Services announced that it has contracted with the company to secure over 500,000 treatment courses through September. This constitutes nearly all of the company's estimated production during that time. The drug will be made available to U.S. hospitals at the price Gilead has set.

In an unusual move, Gilead posted a detailed account on its website of how it arrived at its pricing, given the investment it's put into the drug and the immense global need for a COVID-19 treatment.

"In making our decision on how to price remdesivir, we considered the full scope of our responsibilities," the company wrote. "We started with our immediate responsibility to ensure price is in no way a hindrance to ensuring rapid and broad treatment."

Remdesivir was granted emergency use authorization to treat certain COVID-19 patients by the Food and Drug Administration in May, even though not all clinical trials on such use were encouraging.

On Monday, Gilead shares closed essentially flat on the day, while the broader stock market posted notable gains.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.59 (0.40%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.